ALFRED RUDOLPH, M.D.
Osteopathic Medicine at Liddicoat Dr, Los Altos, CA
License number
California G53270
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
14142 Liddicoat Dr, Los Altos, CA 94022
Phone
(650) 224-0762
Organization information
See more information about ALFRED RUDOLPH at bizstanding.comAlfred Rudolph
San Mateo, CA - Los Altos, CA
Status:
Inactive
Industry:
Medical Doctor's Office
Addresses:
1288 E Hillsdale Blvd, San Mateo, CA 94404
14142 Liddicoat Dr, Los Altos, CA 94022
14142 Liddicoat Dr, Los Altos, CA 94022
Medical Doctor:
Alfred R. Rudolph Medical Doctor, inactive
Professional information
Use Of Thymosin Alpha 1 For Preparing A Medicament For The Treatment Of Stage Iv Malignant Melanoma
US Patent:
8017129, Sep 13, 2011
Filed:
Apr 12, 2007
Appl. No.:
11/734592
Inventors:
Paolo Carminati - Milan, IT
Maria Gabriella Singross, legal representative - Milan, IT
Roberto Camerini - Pomezia, IT
Alfred R. Rudolph - Los Altos Hills CA, US
Eduardo Martins - Foster City CA, US
Maria Gabriella Singross, legal representative - Milan, IT
Roberto Camerini - Pomezia, IT
Alfred R. Rudolph - Los Altos Hills CA, US
Eduardo Martins - Foster City CA, US
Assignee:
SciClone Pharmaceuticals International Ltd - Foster City CA
International Classification:
A61K 39/00
US Classification:
4241981, 514183
Abstract:
It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.
Treatment Of Melanoma
US Patent:
8163702, Apr 24, 2012
Filed:
Apr 13, 2007
Appl. No.:
12/297699
Inventors:
Cynthia W. Tuthill - Menlo Park CA, US
Alfred R. Rudolph - Los Altos Hills CA, US
Alfred R. Rudolph - Los Altos Hills CA, US
Assignee:
SciClone Pharmaceuticals, Inc. - Foster City CA
International Classification:
A61K 38/05, A61K 38/00
US Classification:
514 2191, 514 11, 514 198
Abstract:
An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject.
Dr. Alfred Rudolph, Los Altos Hills CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
14142 Liddicoat Dr, Los Altos Hills 94022
(650) 224-0762 (Phone)
(650) 224-0762 (Phone)
Certifications:
Internal Medicine, 1978
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Upstate Medical University/ College of Health Professions
Graduated: 1975
S U N Y Upstate Medical University Hospital
Upstate Medical University/ College of Health Professions
Graduated: 1975
S U N Y Upstate Medical University Hospital
Immunomodulator Compounds As Vaccine Enhancers
US Patent:
2009007, Mar 19, 2009
Filed:
Apr 21, 2006
Appl. No.:
11/912266
Inventors:
Cynthia W. Tuthill - Menlo Park CA, US
Alfred R. Rudolph - Los Altos Hills CA, US
Alfred R. Rudolph - Los Altos Hills CA, US
Assignee:
SCICLONE PHARMACEUTICALS, INC. - Foster City CA
International Classification:
A61K 39/145, A61K 39/00, A61K 39/29, A61K 39/12, A61K 39/275
US Classification:
4242091, 4241841, 4242261, 4242271, 4242281, 4242041, 4242321
Abstract:
A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficicent animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of an immunomodulator compound is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine.
Thymosin Alpha 1 Peptide/Polymer Conjugates
US Patent:
7297676, Nov 20, 2007
Filed:
Nov 1, 2002
Appl. No.:
10/493690
Inventors:
Alfred R. Rudolph - Los Altos Hills CA, US
Cynthia W. Tuthill - Menlo Park CA, US
Cynthia W. Tuthill - Menlo Park CA, US
Assignee:
SciClone Pharmaceuticals, Inc. - San Mateo CA
International Classification:
A61K 38/17
US Classification:
514 2, 530399
Abstract:
A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in need of immune stimulation.
Alpha Thymosin Peptides As Cancer Vaccine Adjuvants
US Patent:
2010009, Apr 15, 2010
Filed:
Dec 6, 2005
Appl. No.:
11/720909
Inventors:
Gustavo Antonio Moviglia - Buenos Aires, AR
Alfred R. Rudolph - Los Altos Hills CA, US
Alfred R. Rudolph - Los Altos Hills CA, US
Assignee:
SCICLONE PHARMACEUTICALS, INC. - San Mateo CA
International Classification:
A61K 39/00, A61P 35/00
US Classification:
4241851
Abstract:
A pharmaceutical combination and method for enhancing cancer vaccine effectiveness in a subject, utilize an immune response-triggering cancer vaccine capable of eliciting an immune system response in a subject; and a vaccine effectiveness-enhancing amount of an alpha thymosin peptide, which enhances the immune system response in the subject, wherein the cancer vaccine and the alpha thymosin peptide can be administered separately or together.
Thymosin Alpha 1 Peptide/Polymer Conjugates
US Patent:
2008015, Jun 26, 2008
Filed:
Oct 2, 2007
Appl. No.:
11/865816
Inventors:
Alfred R. RUDOLPH - Los Altos Hills CA, US
Cynthia W. TUTHILL - Menlo Park CA, US
Cynthia W. TUTHILL - Menlo Park CA, US
Assignee:
SCICLONE PHARMACEUTICALS, INC. - San Mateo CA
International Classification:
A61K 39/00, A61K 38/02
US Classification:
4241931, 514 2
Abstract:
A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in need of immune stimulation.
Treatment Or Prevention Of Hemorrhagic Viral Infections With Immunomodulator Compounds
US Patent:
8193152, Jun 5, 2012
Filed:
Oct 27, 2005
Appl. No.:
11/577645
Inventors:
Eric C. Mossel - League City TX, US
Cynthia W. Tuthill - Menlo Park CA, US
Alfred R. Rudolph - Los Altos Hills CA, US
Clarence J. Peters - Galveston TX, US
Cynthia W. Tuthill - Menlo Park CA, US
Alfred R. Rudolph - Los Altos Hills CA, US
Clarence J. Peters - Galveston TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
SciClone Pharmaceuticals, Inc. - Foster City CA
SciClone Pharmaceuticals, Inc. - Foster City CA
International Classification:
A61K 38/05, A61K 31/405, A61P 31/12
US Classification:
514 19, 514419
Abstract:
An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.
Treatment Or Prevention Of Respiratory Viral Infections With Alpha Thymosin Peptides
US Patent:
2010031, Dec 9, 2010
Filed:
Jun 16, 2010
Appl. No.:
12/816959
Inventors:
Alfred R. RUDOLPH - Los Altos Hills CA, US
Cynthia W. TUTHILL - Menlo Park CA, US
Cynthia W. TUTHILL - Menlo Park CA, US
Assignee:
SciClone Pharmaceuticals, Inc. - Foster City CA
International Classification:
A61K 38/22, A61P 31/14, A61P 37/04, A61P 31/12
US Classification:
514 129
Abstract:
An alpha thymosin peptide is administered to a patient having, or at risk of a respiratory viral infection, coronavirus infection and/or SARS.
Methods Of Protecting Against Radiation Damage Using Alpha Thymosin
US Patent:
7897567, Mar 1, 2011
Filed:
Nov 25, 2003
Appl. No.:
10/535835
Inventors:
Alfred R. Rudolph - Los Altos Hills CA, US
Cynthia W. Tuthill - Menlo Park CA, US
Cynthia W. Tuthill - Menlo Park CA, US
Assignee:
SciClone Pharmaceuticals, Inc. - Foster City CA
International Classification:
A61K 38/00
US Classification:
514 12, 514 2
Abstract:
Damage to cells and/or a subject caused by radiation is treated or prevented by administration of an alpha thymosin peptide.